Amicus Therapeutics, Inc.
FOLD
Classifica tra le azioni
#3697
Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery,... Amicus Therapeutics, Inc. is a biotechnology firm dedicated to the discovery, development, and delivery of medical treatments for rare conditions. Its primary commercial offering is Galafold, an orally administered precision medicine designed for adult patients with a confirmed diagnosis of Fabry disease, specifically those exhibiting an amenable galactosidase alpha gene variant as identified by in vitro assay data. The company's pipeline also includes several investigational therapies: AT-GAA, an innovative treatment strategy for Pompe disease; various enzyme replacement therapies aimed at Pompe diseases; and AT-GTX-502, an AAV serotype gene therapy for CLN3. The latter is currently undergoing Phase 1/2 clinical studies to evaluate the safety and efficacy of a single intrathecal administration in patients with CLN3. Additionally, Amicus is exploring therapeutic approaches related to CDKL5, a gene on the X-chromosome that encodes a protein essential for regulating proper brain development. Amicus maintains strategic collaborations and licensing arrangements with prominent entities such as Nationwide Children's Hospital, the University of Pennsylvania, and GlaxoSmithKline. The company was founded in 2002 and is based in Philadelphia, Pennsylvania.
Prezzo delle azioni
$14.49
Ultima sincronizzazione: 2026-04-27
Capitalizzazione di mercato
$4.55B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
71.07%
Paese
US
Scambia Amicus Therapeutics, Inc. (FOLD)
Categoria
Healthcare
Storico del prezzo dell'azione per Amicus Therapeutics, Inc. (FOLD)
Prezzo di chiusura più alto: $14.46 il 2026-04-01
Prezzo di chiusura più basso: $14.43 il 2007-05-01
Prezzo di chiusura più basso: $14.43 il 2007-05-01
Storico del prezzo dell'azione di Amicus Therapeutics, Inc. dal 2007 al 2026
Andamento annuale del prezzo dell'azione
| Anno | Performance |
|---|---|
| 2026 (TTM) | 9.63% |
| 2025 | 19.21% |
| 2024 | -21.90% |
| 2023 | 3.81% |
| 2022 | 8.63% |
| 2021 | -52.22% |
| 2020 | 134.59% |
| 2019 | 0.48% |
| 2018 | -26.50% |
| 2017 | 150.91% |
| 2016 | -44.82% |
| 2015 | 19.71% |
| 2014 | 274.05% |
| 2013 | -52.64% |
| 2012 | 39.12% |
| 2011 | -22.66% |
| 2010 | 11.06% |
| 2009 | -51.83% |
| 2008 | -42.25% |
| 2007 | 0.00% |
Prezzo dell'azione per aziende simili o concorrenti
| Azienda | Prezzo dell'azione | Variazione 1a% | Il paese |
|---|---|---|---|
| $527.18 | 23.67% |
US
|
|
| $251.29 | 814.11% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $890.85 | 6.72% |
NL
|
|
| $752.87 | 7.40% |
CH
|
